Medical Devices U.S. versus international comparable sales growth compares the comparable growth rate of Abbott's Medical Devices segment across its U.S. and international markets.
Abbott reported 8.0% comparable U.S. growth and 8.7% comparable international growth in the second quarter of 2026.
Similar segment growth can hide franchise-level divergence
Heart Failure, Structural Heart, and Neuromodulation showed notably different U.S. and international growth patterns even though the total segment rates were close.
Geography is a mix lens, not a standalone quality score
Differences can reflect product launches, market penetration, reimbursement, procedure volumes, and franchise mix.
Read it with Medical Devices comparable growth and Neuromodulation comparable growth.
Primary source: Abbott Q2 2026 earnings release filed with the SEC.
Part of the Medical Device Portfolio Growth
See It in Company Research
These companies are examples of how the concept is reported or discussed in public filings. Definitions can differ by issuer; these links open company research rather than a normalized metric comparison.
- ABTOpen operating-model research →10 of 10 reviewed concepts in Medical Device Portfolio GrowthPortfolio and geographic growth2 of 2 bridge concepts supportedContinue through this bridge:Medical Devices Comparable Growth
Continue Research
Continue from the concept into the Grizzly Bulls research surface that best matches the next question. These links are research continuations, not recommendations or required steps.
Compare medical device portfolio growth
Compare total Medical Devices comparable growth between U.S. and international markets.
Explore more topics in the Financial Research Encyclopedia.